Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
10.1038/nrm3249 Nat
Weeks 17-21: If tolerated, the dosage will be increased to 2.4 mg once weekly
There is a growing interest in using GLP-1RAs as a therapeutic agent for the treatment of motivation and reward-related behavioral disorders
However, published data allows a directional comparison of the most common GI events: Adverse Event Retatrutide (12 mg) Semaglutide 2.4 mg (STEP trials) Tirzepatide 15 mg (SURMOUNT trials) Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Constipation ~17% ~24% ~12% Important caveat: These numbers come from different trial populations and cannot be directly compared
Values between 5.7% and 6.4% indicate prediabetes, a condition affecting millions of Canadians who often remain unaware of their elevated risk
